Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors
Conclusion
Our study provides valuable insight into non-trial patterns of vascular endothelial growth factor inhibitor-associated hypertension occurrence and severity, and is consistent with prior claims analysis. Identification of optimal strategies to manage vascular endothelial growth factor inhibitor-associated hypertension remain to be clarified with the advent of more comprehensive data sets.
Source: Journal of Oncology Pharmacy Practice - Category: Cancer & Oncology Authors: Thompson, L. A., Saseen, J. J., O'Bryant, C. L., Allen, R. R., Nair, K. V. Tags: Original Articles Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Databases & Libraries | Heart | Hypertension | Study